Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
120 participants
INTERVENTIONAL
2022-09-05
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer
NCT04708847
XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.
NCT00298623
A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days
NCT00964340
Low-dose Neostigmine at TOF Ratio of 0.7 Improves Neuromuscular Recovery
NCT06745492
Efficacy Confirmation Study of NPC-09
NCT04671472
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GNX
GNX / 80mg / BID / PO
GNX80
GNX80 oral intake(BID) for 24 weeks
Placebo
Placebo / BID / PO
Placebo
Placebo oral intake(BID) for 24 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GNX80
GNX80 oral intake(BID) for 24 weeks
Placebo
Placebo oral intake(BID) for 24 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Angiographically confirmed peripheral arterial disease
* Intermittent claudication for more than 6 months
Exclusion Criteria
* Limitation of walking ability due to respiratory insufficiency or to an orthopaedic condition
* Poorly controlled diabetes mellitus
* Positive pregnancy test
* Planned surgical or endovascular procedures other than for the treatment of IC
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SK Chemicals Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Seung-Woon Rha
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GNX_001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.